SIST EN 455-3:2007
(Main)Medical gloves for single use - Part 3: Requirements and testing for biological evaluation
Medical gloves for single use - Part 3: Requirements and testing for biological evaluation
This part of EN 455 specifies requirements for the evaluation of biological safety for medical gloves for single use. It gives requirements for labelling and the disclosure of information relevant to the test methods used.
Medizinische Handschuhe zum einmaligen Gebrauch - Teil 3: Anforderungen und Prüfung für die biologische Bewertung
Dieser Teil der EN 455 legt Anforderungen für die Bewertung der biologischen Sicherheit von medizinischen Einmalhandschuhen fest. Er enthält Anforderungen für die Kennzeichnung und die Angabe von Informationen über die angewendeten Prüfmethoden.
Gants médicaux non réutilisables - Partie 3: Exigences et essais pour évaluation biologique
La présente partie de l?EN 455 spécifie les exigences permettant d?évaluer la sécurité biologique des gants
médicaux a usage unique. Elle mentionne les exigences d?étiquetage des gants et de diffusion des informations
concernant les méthodes d?essai utilisées.
Medicinske rokavice za enkratno uporabo - 3. del: Zahteve in preskusi za biološko ovrednotenje
General Information
Relations
Standards Content (Sample)
SLOVENSKI STANDARD
SIST EN 455-3:2007
01-marec-2007
1DGRPHãþD
SIST EN 455-3:2000
Medicinske rokavice za enkratno uporabo - 3. del: Zahteve in preskusi za biološko
ovrednotenje
Medical gloves for single use - Part 3: Requirements and testing for biological evaluation
Medizinische Handschuhe zum einmaligen Gebrauch - Teil 3: Anforderungen und
Prüfung für die biologische Bewertung
Gants médicaux non réutilisables - Partie 3: Exigences et essais pour évaluation
biologique
Ta slovenski standard je istoveten z: EN 455-3:2006
ICS:
11.140 Oprema bolnišnic Hospital equipment
SIST EN 455-3:2007 en
2003-01.Slovenski inštitut za standardizacijo. Razmnoževanje celote ali delov tega standarda ni dovoljeno.
---------------------- Page: 1 ----------------------
EUROPEAN STANDARD
EN 455-3
NORME EUROPÉENNE
EUROPÄISCHE NORM
December 2006
ICS 11.140 Supersedes EN 455-3:1999
English Version
Medical gloves for single use - Part 3: Requirements and testing
for biological evaluation
Gants médicaux non réutilisables - Partie 3: Exigences et Medizinische Handschuhe zum einmaligen Gebrauch - Teil
essais pour évaluation biologique 3: Anforderungen und Prüfung für die biologische
Bewertung
This European Standard was approved by CEN on 13 October 2006.
CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European
Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national
standards may be obtained on application to the Central Secretariat or to any CEN member.
This European Standard exists in three official versions (English, French, German). A version in any other language made by translation
under the responsibility of a CEN member into its own language and notified to the Central Secretariat has the same status as the official
versions.
CEN members are the national standards bodies of Austria, Belgium, Cyprus, Czech Republic, Denmark, Estonia, Finland, France,
Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania,
Slovakia, Slovenia, Spain, Sweden, Switzerland and United Kingdom.
EUROPEAN COMMITTEE FOR STANDARDIZATION
COMITÉ EUROPÉEN DE NORMALISATION
EUROPÄISCHES KOMITEE FÜR NORMUNG
Management Centre: rue de Stassart, 36 B-1050 Brussels
© 2006 CEN All rights of exploitation in any form and by any means reserved Ref. No. EN 455-3:2006: E
worldwide for CEN national Members.
---------------------- Page: 2 ----------------------
EN 455-3:2006 (E)
Contents Page
Foreword.3
Introduction .4
1 Scope .5
2 Normative references .5
3 Terms and definitions .6
4 Requirements.6
5 Test methods.8
6 Test report .9
Annex A (normative) Method for the determination of aqueous extractable proteins in natural
rubber gloves using the modified Lowry assay .10
Annex B (informative) Immunological methods for the measurement of natural rubber latex
allergens .20
Annex C (informative) Amino acid analysis (AAA) by high pressure liquid chromatography
(HPLC).27
Annex ZA (informative) Relationship between this European Standard and the Essential
Requirements of EU Directive 93/42/EEC Medical Devices.36
2
---------------------- Page: 3 ----------------------
EN 455-3:2006 (E)
Foreword
This document (EN 455-3:2006) has been prepared by Technical Committee CEN/TC 205 “Non-active
medical devices”, the secretariat of which is held by DIN.
This European Standard shall be given the status of a national standard, either by publication of an identical
text or by endorsement, at the latest by June 2007, and conflicting national standards shall be withdrawn at the
latest by June 2007.
This document supersedes EN 455-3:1999.
This document has been prepared under a mandate given to CEN by the European Commission and the
European Free Trade Association, and supports essential requirements of EU Directive 93/42/EEC.
For relationship with EU Directive, see informative Annex ZA, which is an integral part of this document.
EN 455 consists of the following parts under the general title "Medical gloves for single use":
Part 1: Requirements and testing for freedom from holes
Part 2: Requirements and testing for physical properties
Part 3: Requirements and testing for biological evaluation
According to the CEN/CENELEC Internal Regulations, the national standards organizations of the following
countries are bound to implement this European Standard: Austria, Belgium, Cyprus, Czech Republic,
Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania,
Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden,
Switzerland and United Kingdom.
3
---------------------- Page: 4 ----------------------
EN 455-3:2006 (E)
Introduction
Adverse reactions to proteins in latex products have been reported over several years in variable rates of
prevalence. Additionally, adverse reactions due to chemicals, lubricants, sterilization residues, pyrogens or
other residues are described in the scientific literature. Adverse reactions are most often reported due to
gloves made from natural rubber latex, but some of the reactions can also be seen due to gloves made from
synthetic polymers.
EN ISO 10993 specifies requirements and test methods for biological evaluation of medical devices. However
it does not specifically address adverse reactions that can result from the use of medical gloves (e.g,
immediate type allergies). These adverse reactions occur to specific allergens that can be present in gloves.
Several factors contribute to the risk of reaction:
a) the duration and frequency of skin contact with gloves;
b) the exposure to the allergens through direct contact to mucosa and skin (especially when not intact) and
by inhalation of particles;
c) the occlusive nature of the glove/skin interaction during glove use.
This part of EN 455 gives requirements and test methods for evaluation of the biological safety of medical
gloves as part of a risk management process, in accordance with EN ISO 14971 and EN ISO 10993.
4
---------------------- Page: 5 ----------------------
EN 455-3:2006 (E)
1 Scope
This part of EN 455 specifies requirements for the evaluation of biological safety for medical gloves for single use. It
gives requirements for labelling and the disclosure of information relevant to the test methods used.
2 Normative references
The following referenced documents are indispensable for the application of this document. For dated references,
only the edition cited applies. For undated references, the latest edition of the referenced document (including any
amendments) applies.
EN 980, Graphical symbols for use in the labelling of medical devices
EN 1041, Information supplied by the manufacturer with medical devices
EN ISO 10993 (all parts), Biological evaluation of medical devices
EN ISO 14971, Medical devices ― Application of risk management to medical devices (ISO 14971:2000)
EN ISO 21171:2006, Medical gloves ― Determination of removable surface powder (ISO 21171:2006)
European Pharmacopoeia, Monograph 2.6.14 Bacterial Endotoxins: publisher EDQM Council of Europe; 226
avenue de Colmar B.P. 907; F-67029 Strasbourg; France http://www.pheur.org
5
---------------------- Page: 6 ----------------------
EN 455-3:2006 (E)
3 Terms and definitions
For the purposes of this document, the following terms and definitions apply.
3.1
chemicals
substances added or formed during any step of the manufacturing process or in storage which may be
available in the final product
NOTE These can include lubricants, chemical coatings and sterilizing agents. Several chemical ingredients are
commonly used during processing of gloves, some of them are known to cause type IV allergic reactions. The type and
amount of residual chemicals added and finally present are variable.
3.2
endotoxins
lipo-polysaccharides originating from the outer cell-membrane of Gram-negative bacteria
NOTE Endotoxins are one type of pyrogen. Sources of endotoxins can include bacterial contamination of the raw
materials, especially the process water used during manufacturing and manual handling of the gloves.
3.3
powder
all water insoluble material on the surface of a glove that is removed by washing under the conditions of the
test
[EN ISO 21171:2006, definition 3.1]
NOTE This includes both deliberately added powder and other processing aids or materials accidentally present
which may be readily detached from the surface of the glove. For the purpose of this European Standard any glove
containing 2 mg or less powder is a powder-free glove and more than 2 mg is a powdered glove (for requirement see 4.4.).
3.4
process limit
highest value likely to be encountered for a validated manufacturing process
3.5
proteins, allergenic
proteins capable of causing a type I allergic reaction
3.6
proteins, leachable
aqueous proteins and peptides extractable from the final product
3.7
pyrogens
substances creating fever in rabbits which can be related to fever and other adverse reactions in humans
4 Requirements
4.1 General
Medical gloves for single use shall be evaluated as described in the EN ISO 10993 series. Part 1 of this series
describes the general principles governing the biological evaluation of medical devices and shall be used to
select the appropriate tests as described in other parts of the series.
A risk management process in accordance with EN ISO 14971 shall be established.
6
---------------------- Page: 7 ----------------------
EN 455-3:2006 (E)
4.2 Chemicals
Gloves shall not be dressed with talcum powder (magnesium silicate).
Chemicals known to be allergenic shall be avoided if technical alternatives exist. Wherever possible allowable
limits for leachable residual chemicals shall be established using EN ISO 10993-17 and these limits shall be
complied with. Wherever this is not possible, the residual chemicals level shall be "As Low As Reasonably
Practicable" (ALARP – see EN ISO 14971).
The manufacturer shall disclose, upon request, a list of chemical ingredients either added during
manufacturing or already known to be present in the product such as accelerators, antioxidants and biocides,
that are known to cause adverse health effects based on current data.
4.3 Endotoxins
The manufacturer shall monitor the endotoxin contamination of sterile gloves using the test method specified
in 5.1 if the gloves are labelled with 'low endotoxin content'. For such labelled gloves the endotoxin content
shall not exceed the limit of 20 endotoxin units per pair of gloves.
4.4 Powder
For powder free gloves the total quantity of powder residues determined according to the test method under
5.2 shall not exceed 2 mg per glove. Any glove containing more than 2 mg powder is a powdered glove.
4.5 Proteins, leachable
The manufacturer shall monitor the process limit of leachable protein in the finished gloves containing natural
rubber latex by the method specified in 5.3 and described in Annex A. The documentation of these results
shall be retained. The results of the test and applied test method shall be made available on request.
The leachable protein level shall be "As Low As Reasonably Practicable" (ALARP).
NOTE Proteins, allergenic: This European Standard specifies a method measuring a broad approximation for the
allergen content, e.g. leachable proteins. There is no direct correlation between leachable proteins and allergen content.
Quantitative methods to measure allergenic proteins are under development, as described in Annex B.
4.6 Labelling
In addition to the labelling specified in EN 1041 and the relevant symbols given in EN 980, the following
requirements apply:
a) medical gloves containing natural rubber latex shall be labelled at least on the packaging, of the smallest
packaging unit with the following symbol (EN 980 general requirements for symbols apply);
7
---------------------- Page: 8 ----------------------
EN 455-3:2006 (E)
Figure 1 — Symbol for products containing natural rubber latex
b) the labelling shall include the following or equivalent warning statement together with the symbol:
‘(Product) contains natural rubber latex which may cause allergic reactions, including anaphylactic
responses;
c) the labelling shall include a prominent indication of whether the glove is powdered or powder-free;
d) sterile powdered gloves shall be labelled with the following or equivalent:
'CAUTION: Surface powder shall be removed aseptically prior to undertaking operative procedures in
order to minimize the risk of adverse tissue reactions;
NOTE 2 This caution statement can be given on the inner wrapping.
e) for any medical glove containing natural rubber latex the product labelling shall not include:
any term suggesting relative safety, such as low allergenicity, hypoallergenicity or low protein;
any unjustified indication of the presence of allergens;
f) if the manufacturer labels the gloves with the protein content, the process limit, measured as specified in
5.3 shall be given.
NOTE 3 This does not allow a protein labelling claim below 50 µg/g. Lower claims are not considered to be reliable
given the expected process variation in manufacture and inter-laboratory testing.
5 Test methods
5.1 Endotoxins
Except where non-removable interferences in the Limulus Amoebocyte Lysate (LAL) procedures are present,
selection, validation and use of technique shall be as described in the European Pharmacopoeia, Monograph
2.6.14, "Bacterial Endotoxins". The results shall be expressed in endotoxin units (E.U.) per pair of gloves.
NOTE 1 Where non-removable interferences in the LAL procedure are present, the bacterial endotoxin level cannot be
accurately measured.
The minimum number of pairs of gloves recommended to be tested in relation to the number of items in the
batch are two pairs of gloves for a batch size under thirty, three pairs of gloves for a batch size thirty to one
hundred, and 3 % of a batch above size one hundred, up to a maximum of ten pairs of gloves per batch.
8
---------------------- Page: 9 ----------------------
EN 455-3:2006 (E)
The outside surface of a pair of gloves is extracted with 40 ml of endotoxin-free water (Water LAL, European
Pharmacopoeia, for not less than 40 min and not more than 60 min at a temperature between 37 °C and
40 °C in a way to ensure that all surfaces come into contact with the extraction medium. The extract is
centrifuged, if necessary, for 15 min at 2000 g to remove particles after which the liquid component is
decanted and tested for endotoxin immediately afterwards.
NOTE 2 Other methods for the analysis of endotoxins exist and these can be used for routine quality control purposes
provided they have been validated and a correlation established against the reference method specified in this European
Standard.
5.2 Powder
The test method for the determination of powder residues described in EN ISO 21171 shall be used.
5.3 Proteins, leachable
The test method for the analytical determination of leachable protein shall be the modified Lowry method
given in Annex A or a suitably validated method which has been correlated against the modified Lowry
method.
NOTE 1 An example of a validated analytical method is given in Annex C.
NOTE 2 The immunological methods in Annex B are currently not validated against the modified Lowry method but
may be correlated to clinical response data.
6 Test report
The test report shall include at least the following information:
a reference to this European Standard, i.e. EN 455-3;
the type of gloves and manufacturing batch code;
the name and address of the manufacturer or distributor and of the test laboratory if different;
the date of the test;
the description of the test method applied;
the test results.
9
---------------------- Page: 10 ----------------------
EN 455-3:2006 (E)
Annex A
(normative)
Method for the determination of aqueous extractable proteins in natural
rubber gloves using the modified Lowry assay
A.1 Scope
This method is for the determination of the amount of aqueous extractable proteins in gloves for medical use
made from natural rubber (NR). It has been validated during inter-laboratory round-robin tests. The lower
quantification limit is approximately 10 µg protein per g of glove (i.e. 2 µg protein per ml of extract) depending
on the glove weight.
Chemicals such as surfactants, accelerators and antioxidants added to the NR latex during the manufacture of
the gloves can interfere with the colour development during the determination, some materials may reduce
colour development while others can increase it. If the test method yields results that appear erroneous due to
interferants, then any validated amino acid analysis method can be used (as an example see the method
given in Annex C).
NOTE Persons using this method should be familiar with normal laboratory practice. This method does not purport to
address all of the safety problems, if any, associated with its use. It is the responsibility of the user to establish appropriate
safety and health practices and to ensure compliance with any national regulatory conditions.
A.2 Principle
Water soluble proteins are extracted into a buffer solution and then precipitated with acids in the presence of
sodium deoxycholate to concentrate them and to separate them from water soluble substances which may
interfere with the determination. The precipitated proteins are redissolved in alkali and quantified
colorimetrically by a modified Lowry method. The assay is based on the reaction of proteins with copper and
Folin reagent in an alkaline medium to give a characteristic blue colour. Spectrophotometric measurements
are performed at a fixed wavelength in the range 600 nm to 750 nm.
A.3 Reagents
A.3.1 General
Wherever water is called for, double distilled water or water of equivalent quality should be used. All other
reagents should be of analytical quality.
A.3.2 Extractant
A.3.2.1 N-tris-[Hydroxymethyl]-methyl-2-aminoethanesulfonic acid (TES), hemisodium salt.
A.3.2.2 Extraction buffer, 0,1 M, prepared by dissolving 24 g TES (A.3.2.1) in 1 l water. Any equivalent
buffering system can be used provided the solution has sufficient buffering capacity to hold a pH of 7,4 ± 0,2
in the glove extracts.
NOTE Prepare a sufficient quantity for the glove extraction (A.6.2), the preparation of the protein standard solutions
(A.6.3.2) and the blank.
10
---------------------- Page: 11 ----------------------
EN 455-3:2006 (E)
A.3.2.3 Dye solution, Bromophenol blue, sodium salt solution, prepared by dissolving 100 mg
bromophenol blue in 1 l of water. Prepare a fresh solution every four weeks.
A.3.3 Lowry protein assay reagents
NOTE Reagents can either be prepared from off-shelf chemicals [1] or be purchased as commercial kits. The method
1)
for this European Standard was validated with a commercial kit.
A.3.3.1 Reagent A, Copper reagent (alkaline copper tartrate or copper citrate solution).
A.3.3.2 Reagent B, Diluted Folin reagent.
A.3.4 Sodium hydroxide, 0,1 M aqueous solution.
A.3.5 Sodium deoxycholate (DOC), 3,47 mM, prepared by dissolving 0,15 g sodium deoxycholate in water
and diluting with water to 100 ml. Do not use this solution more than four weeks after it has been prepared.
A.3.6 Trichloroacetic acid (TCA), 4,4 mM in water, prepared by dissolving 72 g TCA in water and diluting
with water to 100 ml.
A.3.7 Phosphotungstic acid (PTA), prepared by dissolving 72 g PTA in water and diluting with water to
100 ml. Do not use this solution more than four weeks after it has been prepared.
2)
A.3.8 Ovalbumin, from chicken egg lyophilized, salt-free.
A.4 Apparatus
A.4.1 Synthetic gloves, powder-free.
A.4.2 Centrifuge, capable of reaching at least 6000 g
A.4.3 Centrifuge tubes, 30 ml or 50 ml polypropylene tubes with a low protein binding capacity of 10 µg per
tube or less. Do not use glass equipment because of surface absorption of proteins.
NOTE A method for the determination of protein binding capacity is described in A.5.
A.4.4 Filter units, single use, with 0,22 µm pore size and a low protein binding capacity of 10 µg per filter or
less.
NOTE A method for the determination of protein binding capacity is described in A.5.
A.4.5 Syringes, disposable, 20 ml, made of polyethylene or polypropylene.
A.4.6 Micro tubes, 2 ml, made of polypropylene.
A.4.7 Quartz cuvette, of 1 cm path length.
A.4.8 Microtitre plate, with 96 wells, flat bottomed, made of polystyrene, or disposable cuvettes (A.4.9).
1)
Lowry Micro DC Protein Assay Kit (catalogue number 500-0116), available from BioRad Laboratories, 2000 Alfred
Nobel Drive, Hercules, CA 9456547, USA. This information is given for the convenience of users of this European
Standard and does not constitute an endorsement by CEN of the product named.
2)
This ovalbumin is prepared from fresh chicken egg whites by ammonium sulfate fractionation and repeated
crystallisation at pH 4,5; for example Sigma A 5503, chicken egg albumin, Grade V, available from Sigma Chemical Co.
P.0. Box 14506, St Louis, MO 63178, USA is suitable. This information is given for the convenience of users of this
European Standard and does not constitute an endorsement by CEN of the product named.
11
---------------------- Page: 12 ----------------------
EN 455-3:2006 (E)
A.4.9 Disposable cuvettes, 1,5 ml semi-micro, 1 cm path length, made of polystyrene
A.4.10 Microplate reader, operating at a wavelength in the range 600 nm to 750 nm
A.4.11 Spectrophotometer, operating in the wavelength range 230 nm to 750 nm.
A.4.12 Vortex mixer.
A.4.13 Micropipettes, with disposable polypropylene tips.
A.4.14 Clamps, for sealing gloves watertight during extraction. Pairs of aluminium bars lined with foam
rubber and which can be screwed together (see Figure A.1) or 170 mm long plastic clips for haemodialysis are
suggested.
A.4.15 Shaker.
A.5 Measurement of protein binding capacity
A.5.1 General
Single use polypropylene equipment (which is known to have a low protein binding capacity) is recommended
for use throughout. The protein binding capacity shall be checked by the following methods before using
centrifuge tubes or filter units from a new batch. The test shall be carried out within one day.
A.5.2 Protein binding capacity of centrifuge tubes
A.5.2.1 Prepare in a centrifuge tube (A.4.3) 30 ml of a reference solution containing 10 µg/ml ovalbumin
by dilution of the protein stock solution (A.6.3.1) with the extraction buffer (A.3.2.2).
A.5.2.2 Transfer 10 ml test portions of the ovalbumin solution (A.5.2.1) to each of two fresh centrifuge
tubes and shake the tubes on a shaker (A.4.15) ensuring that the whole surface is wetted by the solution.
After 30 min transfer the solutions to a further two tubes and shake them. Repeat the procedure until each of
the 10 ml portions has been exposed to five tubes. Store the remaining test solutions.
A.5.2.3 Determine the concentration of the protein in the reference solution and two test solutions in
triplicate using the method given in A.6.4 to A.6.6.
A.5.2.4 Calculate the average absorbed ovalbumin from the expression:
10(R−T )
O =
5
= 2 (R-T)
where
O is the absorbed ovalbumin in µg/tube;
R is the mean of three determinations of the ovalbumin content of the reference solution in µg/ml;
T is the mean ovalbumin content of the test solution after passage through the tubes
(i.e. the mean of six values) in µg/tube.
The value for the absorbed albumin (O) shall be less than 10 µg per tube, otherwise the tubes are unsuitable
for the determination.
12
---------------------- Page: 13 ----------------------
EN 455-3:2006 (E)
A.5.3 Protein binding capacity of filter units
A.5.3.1 Prepare in a centrifuge tube (A.4.3) 30 ml of a reference solution containing 10 µg/ml ovalbumin
by dilution of the protein stock solution (A.6.3.1) with the extraction buffer (A.3.2.2).
A.5.3.2 Prepare two stacks of five filter units (A.4.4). Filter 10 ml of the reference solution through each
filter stack into a centrifuge tube (A.4.3).
A.5.3.3 Determine the protein content of the reference solution and the two test solutions in triplicate
using the method given in A.6.4 to A.6.6.
A.5.3.4 Calculate the average absorbed ovalbumin from the expression:
10(R−T )
O =
5
= 2 (R-T)
where
O is the absorbed ovalbumin in µg/tube;
R is the mean of three determinations of the ovalbumin content of the reference solution in µg/ml;
T is the mean ovalbumin content of the test solution after passage through the filter units
(i.e. the mean of six values) in µg/tube.
The value for the absorbed albumin (O) shall be less than 10 µg per filter, otherwise the filters are unsuitable
for the determination.
A.6 Procedure
A.6.1 General
The procedure involves the extraction of the gloves followed by purification and concentration of the extract by
a factor of five. The determination on the extract is performed by reference to a calibration curve prepared
using standard protein solutions which have been concentrated in the same manner.
The extraction procedure employed is one in which the inside of one glove and the outside of a second glove
are extracted simultaneously. It allows the extraction volume to be minimized at 25 ml and avoids any loss of
proteins to container surfaces because the extraction buffer is only exposed to the gloves.
NOTE Alternative extraction procedures may be used if they are validated against this method. A round robin test by
selected laboratories in Europe and in the USA revealed equivalent results with the ASTM Standard D5712:1995 [2] when
extracting cut pieces of gloves for 2 h at 25 °C in TES buffer pH 7,4.
A.6.2 Extraction procedure
A.6.2.1 Use synthetic gloves (A.4.1) to handle the glove samples used for the extraction.
Take eight glove specimens of the same size and the same lot and separate them into four pairs. In the case
of hand-specific gloves, choose four right-handed and four left-handed samples and separate them into two
right-handed and two left-handed pairs.
13
---------------------- Page: 14 ----------------------
EN 455-3:2006 (E)
Mark the cuff of one glove of each pair at a point (200 ± 10) mm from the tip of the middle finger and weigh the
glove (m ) to the nearest 0,1 g. For each pair, insert the second glove inside the marked one so that they fit
1
together as shown in Figure A.1 a).
NOTE The method for introducing one glove into the other is not of critical importance provided the gloves are
manipulated as little as possible. One way it can be achieved is by sliding a rod in the thumb and the little finger of the
inner glove to help to introduce them into the corresponding fingers of the second glove. Use the rods to insert the three
other fingers.
A.6.2.2 Pour into the inner glove a sufficient quantity of dye solution (A.3.2.3) to fill all five fingers.
Introduce 25 ml extraction buffer (A.3.2.2) at (25 ± 5) °C between inner and outer gloves. For larger gloves
this volume may be increased to a maximum of 50 ml. Remove most air bubbles and seal the gloves with the
clamp (A.4.14) at the 20 cm mark so as to produce a watertight seal as shown in Figure A.1 b).
A.6.2.3 Fix the gloves to the shaker (A.4.15) and shake for (120 ± 5) min at (25 ± 5) °C.
A.6.2.4 Remove the clamp and separate the gloves carefully. Take care not to contaminate the extract
with the dye solution. If the extract is coloured blue, it shall be discarded and the extraction repeated with
fresh gloves.
A.6.2.5 Carefully transfer the extract into a centrifuge tube (A.4.3) and clarify the extract either by
centrifugation at not less than 2000 g for 15 min or filtration through a single use filter unit (A.4.4), or a
combination of both as appropriate. Either store the resulting clear solution refrigerated at 2 °C to 8 °C and
carry out the determination within 48 h or alternatively
...
Questions, Comments and Discussion
Ask us and Technical Secretary will try to provide an answer. You can facilitate discussion about the standard in here.